KAZAKHSTAN PLANS TO LAUNCH DOMESTIC VACCINE INTO MASS PRODUCTION IN FEBRUARY
Share :
Download PDF :

10.09.2020


New Europe (9 September 2020)

Kulpash Konyrova

 

Kazakh scientists are planning to launch the domestic vaccine into mass production in February, Kazakh Foreign Minister Mukhtar Tleuberdi told a joint press conference with Russian Foreign Minister Sergei Lavrov on February 9.

“Kazakh scientists have also developed a vaccine. They are just starting testing procedures. Our scientists plan to launch mass production of this vaccine in about February,” Tleuberdi said.

Lavrov also recalled that Russia and Kazakhstan have agreements on the Sputnik V vaccine. “At the end of August, the Deputy Prime Minister of Kazakhstan, Mr. (Roman) Sklyar was in Moscow. This was all discussed. There are already concrete general approaches, practically agreements on concrete steps in this direction, including the supply of a vaccine for conducting clinical trials in conjunction with vaccination,” Lavrov said.

Earlier, the Kazakh Minister of Health Aleksey Tsoi said that negotiations were underway on the possible purchase of the Russian vaccine Sputnik V against coronavirus, the Oxford vaccine of the AstraZeneca company, and Kazakh scientists are also developing their own vaccine. 627 people expressed their desire to take part in clinical trials of the Kazakhstani vaccine QazCovid-in.

On July 31, the World Health Organization (WHO) included the Kazakhstan inactivated coronavirus vaccine QazCovid-in️ in the list of candidate vaccines approved for clinical trials. The seven vaccine creators, led by the institute’s director, became the first volunteers to receive the vaccine to protect their safety while working with the virus. According to the test results, all have developed antibodies to the virus, the employees are healthy and continue to work within the framework of the scientific and technical programme.

https://www.neweurope.eu/article/kazakhstan-plans-to-launch-domestic-vaccine-into-mass-production-in-february/

 




No comments yet.